Approximately half of all kidney transplant recipients will experience graft failure during their lifetime, most commonly owing to chronic rejection or recurrent primary disease.1 For patients, graft failure can lead to inferior survival and quality of life associated with a return to dialysis. At a system level, allograft failure increases cost of care while also intensifying the demand for organs for transplantation.2 As a result, even marginal increases in allograft longevity may have significant patient- and system-level benefits.